Robert Spiera, Sebastian Unizony, Kenneth J. Warrington, Jennifer Sloane Lazar, Angeliki Glannelou, Michael C Nivens, Bolanie Akinlade, Wanling Wong, Yong Lin, Frank Buttgereit, Valerie Devauchelle-Pensec, Andrea Rubbert-Roth, Bhaskar Dasgupta
Abstract or description:
The poster describes the results of SAPHYR study that assessed the safety and efficacy of sarilumab in PMR patients who flared on tapering glucocorticoid (GC) dose. The study met its primary endpoint with higher number of patients achieving sustained remission with sarilumab 200 mg Q2W + 14-week GC taper when compared with patients receiving placebo + 52-week GC taper.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.